- Home
- EQBK vs ABUS Comparison
EQBK vs ABUS Comparison
Compare EQBK & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQBK
- ABUS
- Stock Information
- Founded
- EQBK 2002
- ABUS 2005
- Country
- EQBK United States
- ABUS United States
- Employees
- EQBK N/A
- ABUS N/A
- Industry
- EQBK Major Banks
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- EQBK Finance
- ABUS Health Care
- Exchange
- EQBK Nasdaq
- ABUS Nasdaq
- Market Cap
- EQBK 622.8M
- ABUS 592.8M
- IPO Year
- EQBK 2015
- ABUS N/A
- Fundamental
- Price
- EQBK $38.34
- ABUS $3.24
- Analyst Decision
- EQBK Hold
- ABUS Strong Buy
- Analyst Count
- EQBK 6
- ABUS 4
- Target Price
- EQBK $44.20
- ABUS $5.50
- AVG Volume (30 Days)
- EQBK 84.6K
- ABUS 1.3M
- Earning Date
- EQBK 04-15-2025
- ABUS 05-05-2025
- Dividend Yield
- EQBK 1.56%
- ABUS N/A
- EPS Growth
- EQBK 543.36
- ABUS N/A
- EPS
- EQBK 3.93
- ABUS N/A
- Revenue
- EQBK $224,600,000.00
- ABUS $6,171,000.00
- Revenue This Year
- EQBK $16.00
- ABUS $14.57
- Revenue Next Year
- EQBK $12.49
- ABUS $15.84
- P/E Ratio
- EQBK $9.61
- ABUS N/A
- Revenue Growth
- EQBK 56.29
- ABUS N/A
- 52 Week Low
- EQBK $31.75
- ABUS $2.63
- 52 Week High
- EQBK $50.85
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- EQBK 52.75
- ABUS 50.09
- Support Level
- EQBK $35.92
- ABUS $2.71
- Resistance Level
- EQBK $37.06
- ABUS $3.32
- Average True Range (ATR)
- EQBK 1.64
- ABUS 0.21
- MACD
- EQBK 0.33
- ABUS 0.00
- Stochastic Oscillator
- EQBK 81.88
- ABUS 63.86
About EQBK Equity Bancshares Inc.
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 71 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.